BioSpace News Archive

According to Nova one advisor, the U.S. Generic Drug market size was valued at US$ 123.75 billion in 2021 and is expected to hit US$ 155.82 billion by 2030, growing at a compound annual growth rate (CAGR) of 2.59% from 2022 to 2030.

Genetic toxicology testing is designed to evaluate the compounds that induce genetic mutations or chromosomal damage.

The global biologics contract development market was estimated at USD 5.61 billion in 2021 and it is expected to surpass around USD 13.7 billion by 2030, poised to grow at a CAGR of 10.43% from 2022 to 2030

Ichor Life Sciences, a preclinical contract research organization, announced a $1.5 million investment in MitoChem Therapeutics.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced statistically significant and clinically meaningful results from the second interim analysis of the key secondary endpoint of overall survival (OS) in the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy.

Athersys, Inc. (Nasdaq: ATHX) today announced that it has entered into a definitive agreement with a single healthcare-focused U.S. institutional investor for the purchase and sale of 48,000,000 shares of the Company’s common stock.

Personalis, Inc. has announced a collaboration with BC Cancer to deploy a personalized liquid biopsy-based research use only (RUO) assay for a study of patients with colorectal and pancreatic cancers.

Probo Medical (“Probo”), a leading global provider of medical imaging equipment, parts, repair, and service, announced the acquisition of Mi Healthcare.

Daewoong Pharmaceutical is a publicly traded South Korean pharmaceutical company that develops, manufactures, and commercializes pharmaceuticals globally today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to initiate a Phase 1 clinical trial of DWP213388, a new drug candidate being developed for autoimmune diseases.

Nuvig Therapeutics, Inc. announced today the appointment of Joanne Quan, M.D., as Chief Medical Officer.